Indications for OMNIPAQUE 350:
IV administration: in adults, for angiocardiography (ventriculography, selective coronary arteriography), aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches, computerized tomography [CT] head and body imaging, intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels, peripheral arteriography, and excretory urography. In children, for angiocardiography (ventriculography, pulmonary arteriography, venography, and studies of the collateral arteries) and aortography, including the aortic root, aortic arch, ascending and descending aorta. Oral: in adults, for oral radiographic examination of the GI tract. Oral in conjunction with IV: in adults and children, for CT of the abdomen. Intraarticular: in adults, for arthrography. Body cavity: in children, for voiding cystourethrography (VCU).
Adults and Children:
See full labeling for dosing based on procedure.
Omnipaque 140 and 350: intrathecal use.
Risks with inadvertent intrathecal administration of Omnipaque 140 and 350 injection.
Do not administer Omnipaque 140 and 350 intrathecally: severe reactions may occur (eg, death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, brain edema). Have emergency treatment and trained personnel readily available. Monitor for hypersensitivity reactions. Cardiovascular disease (monitor). Pheochromocytoma. Homozygous sickle cell disease. Homocystinuria: avoid angiocardiography. Thyroid disorder. Renal impairment or risk of (eg, diabetes, dehydration, multiple myeloma, CHF, advanced vascular disease). History of severe cutaneous reaction: avoid. Ensure adequate hydration. Avoid extravasation (esp. in arterial or venous disease). Elderly. Pregnancy. Nursing mothers: bottle feeding may be substituted for breastfeeding, for 10hrs after administration.
Radiographic contrast medium.
Concomitant drugs that lower seizure threshold (eg, phenothiazines): not recommended with intrathecal use. Discontinue metformin at time of, or prior to Omnipaque in patients with eGFR 30–60mL/min/1.73m2, history of hepatic impairment, alcoholism, heart failure, or will be given intra-arterial contrast; reevaluate eGFR 48hrs after procedure and restart metformin if renally stable. Increased risk of kidney injury with concomitant nephrotoxic drugs or diuretics. Discontinue CNS active drugs (eg, MAOIs, tricyclics, CNS stimulants, analeptics, tranquilizers, antipsychotics) ≥48hrs before myelography and for ≥24hrs post-procedure. Caution with beta-blockers. May interfere with thyroid uptake of radioactive iodine and decrease efficacy in thyroid carcinoma for up to 6–8 weeks. May reduce iodine-binding capacity of thyroid tissue for up to 2 weeks.
Intrathecal: headache, backache, neckache, stiffness, neuralgia, nausea, vomiting, dizziness. IV: inj site reactions, pain, arrhythmias, angina/chest pain, hypotension, vertigo, vision abnormalities, headache, taste perversion, nausea; severe skin reactions (eg, SJS, TEN, AGEP, DRESS). Oral: diarrhea, nausea, vomiting, abdominal pain, flatulence, headache; children: also, fever, hypotension, urticaria. Body cavities: pain, swelling, heat sensation. Angiocardiography: thromboembolism. Hypersensitivity reactions, acute kidney injury, cardiovascular reactions.
Omnipaque 140 (50mL)—10; Omnipaque 180 (10mL, 20mL)—10; Omnipaque 240 (10mL, 20mL, 50mL, 100mL, 150mL, 200mL)—10; Omnipaque 300 (10mL, 30mL, 50mL, 75mL, 100mL, 125mL, 150mL, 200mL)—10; Omnipaque 350 (50mL, 75mL, 100mL, 125mL, 150mL, 200mL, 250mL)—10